(Q35583342)

9 August 2017

1 reference

title

New patterns of HIV-1 resistance during HAART (English)

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

highly active antiretroviral therapy

1 April 2024

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616723

viral multiple drug resistance

1 April 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616723

1 April 2024

author name string

E. Fumero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616723

1 April 2024

D. Podzamczer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616723

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14616723

1 April 2024

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

http://www.clinicalmicrobiologyandinfection.com/article/S1198743X14638155/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616723

https://api.elsevier.com/content/article/PII:S1198743X14638155?httpAccept=text/xml

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

https://api.elsevier.com/content/article/PII:S1198743X14638155?httpAccept=text/plain

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Clinical Microbiology and Infection

1 April 2024

published in

1 reference

9 August 2017

volume

9

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

1077-1084

1 reference

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

9 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Individualising HIV treatment--pharmacogenetics and immunogenetics

1 April 2024

2

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Development of Zidovudine Resistance Mutations in Patients Receiving Prolonged Didanosine Monotherapy

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 April 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Extent and importance of cross-resistance to efavirenz after nevirapine failure

1 April 2024

31

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Therapy for the treatment-experienced patient

1 April 2024

32

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance

1 April 2024

33

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

1 April 2024

36

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts

1 April 2024

40

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 April 2024

41

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro

1 April 2024

43

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

1 April 2024

44

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

1 April 2024

45

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

1 April 2024

47

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

1 April 2024

49

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Atazanavir: a novel HIV-1 protease inhibitor

1 April 2024

50

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]

1 April 2024

59

1 reference

https://api.crossref.org/works/10.1046/J.1469-0691.2003.00730.X

1 April 2024

Identifiers

1 reference

9 August 2017

1 reference